Ph.D. Dinesh V Patel - 12 May 2026 Form 4/A - Amendment Insider Report for Protagonist Therapeutics, Inc (PTGX)

Reporting relationship: President and CEO, Director
Issuer ticker: PTGX
Reported as of: 12 May 2026
Net transaction value: -$7,509,000
SEC form: 4/A - Amendment
Accepted by SEC: 14 May 2026, 20:06:46 UTC
Original report date: 12 May 2026
Prior SEC filing: 24 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.

Key filing fact

Ph.D. Dinesh V Patel filed Form 4/A - Amendment for Protagonist Therapeutics, Inc (PTGX) on 14 May 2026.

Key facts

This page summarizes Ph.D. Dinesh V Patel's Form 4/A - Amendment filing for Protagonist Therapeutics, Inc (PTGX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 May 2026, 20:06.

Change

Previous filing in this sequence was filed on 24 Apr 2026.
Current net transaction value: -$7,509,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001120477 Primary reporting owner

PATEL DINESH V PH D

Relationship: President and CEO, Director
Address: C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK
Signature: /s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.
Signature date: 14 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTGX transaction

Common Stock

Options Exercise

Transaction value
Shares: +75,000
Change %: +14%
Price: $21.58^*
Shares after: 598,478
Date: 12 May 2026
Ownership: Direct
Footnotes: F1

PTGX transaction

Common Stock

Sale

Transaction value: $7,509,000
Shares: -75,000
Change %: -13%
Price: $100.12
Shares after: 523,478
Date: 12 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTGX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -75,000
Change %: -25%
Price: $0.000000^*
Shares after: 225,000
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 75,000
Exercise price: $21.58
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This Form 4 Amendment is being filed to clarify that the transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026 and to check the appropriate box which appeared unchecked on the original Form 4 filing.

Footnote F2

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.83 to $103.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F3

These stock options are fully vested and will expire on October 11, 2026.